Teva Pharmaceuticals is now facing legal action as a federal complaint has been fired against the company, along with other generic drug manufacturers, alleging the companies colluded in a pay-for-delay scheme.
The class action suit accuses the companies of colluding to keep the generic form of the drug Aggrenox off pharmacy shelves. The drug is used to treat low-risk stroke patients.
According to court documents, Barr Pharmaceuticals, which is also named as a defendant in the case, began looking into regulatory approval for the generic in 2007. But Borhringer, which sold the brand name Aggrenox, entered into an exclusive payment agreement – a pay-for-delay agreement – to delay the release of the generic drug to prevent financial losses. The lawsuit alleges Boehringer paid Barr to delay the drug’s release until 2015.
Reports say the third defendant named is Duramed Pharmaceuticals.
Full Content: Penn Record
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI